KalVista Pharmaceuticals provided unaudited global net product revenue results of approximately $35 million for the fourth quarter and $49 million for the full year 2025 for EKTERLY (sebetralstat), their novel plasma kallikrein inhibitor for hereditary angioedema (HAE).
The company received 1,318 patient start forms for EKTERLY in the US through December, indicating rapid adoption as the first oral on-demand HAE treatment.
Partnership with Multicare Pharma for commercialization in Latin America marks the third commercial partnership in 10 months.
Steady Growth
Steady execution and growing utilization of EKTERLY boosted global net product revenue to $49 million in 2025.
International Expansion
Strong uptake in Germany and plans to enter other major markets in 2026 demonstrate the global market potential of EKTERLY.
Pediatric Expansion
Filing a new drug application in Q3 for pediatric patients aged 2-11 years signifies the commitment to accessibility and broader patient reach.
- EKTERLY's emergence as the preferred on-demand HAE treatment is attributed to high demand, positive prescribing behaviors, and patient satisfaction.
- Patient refills surpassing initial prescriptions in Q4 indicate growing real-world familiarity and satisfaction with EKTERLY.
KalVista Pharmaceuticals' strong performance post EKTERLY launch, global expansion plans, and focus on patient accessibility position them as a key player in the HAE treatment market.